Literature DB >> 23692654

Myelodysplastic syndromes and autoimmune diseases--case series and review of literature.

Omar Al Ustwani1, Laurie A Ford, Sheila J N Sait, Anne Marie W Block, Maurice Barcos, Carlos E Vigil, Elizabeth A Griffiths, James E Thompson, Eunice S Wang, Julian Ambrus, Meir Wetzler.   

Abstract

Our objective was to recognize the association of autoimmune diseases (AD) in patients with myelodysplastic syndromes (MDS) and understand how this association could affect prognosis and management of both diseases. We describe our cohort of 10 patients and 34 patients reported in the English literature in addition to ten cohort studies. Interestingly, four cases showed improvement in AD after 5-azacitidine treatment. The mechanism(s) of the association between AD and MDS are discussed. Treatment could be targeted against AD, MDS or both, though based on recent reports, treating MDS with hypomethylating agents alone could improve the associated AD.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23692654      PMCID： PMC3699612          DOI： 10.1016/j.leukres.2013.04.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  56 in total

1.  The autoimmune manifestations associated with myelodysplastic syndrome respond to 5-azacytidine: a report on three cases.

Authors:  Sylvain Pilorge; Luc Moulonguet Doleris; François Dreyfus; Sophie Park
Journal:  Br J Haematol       Date:  2011-01-31       Impact factor: 6.998

2.  [Relapsing polychondritis associated with myelodysplasia and acute eosinophilic leukemia].

Authors:  J Várkonyi; L Jakab; T Szombathy; R Vámos; A Zalatnai; P Nagy
Journal:  Orv Hetil       Date:  1997-04-13       Impact factor: 0.540

3.  Large vessel (Takayasu's) arteritis in a patient with myelodysplastic syndrome: is there a common pathogenesis?

Authors:  Matan J Cohen; Anat Shyman; Martine Klein; Aryeh Ben-Yehuda; Alan Rubinow; Reuven Or; Neta Goldschmidt
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-02

4.  Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients.

Authors:  T Okamoto; M Okada; A Mori; K Saheki; H Takatsuka; H Wada; A Tamura; Y Fujimori; Y Takemoto; A Kanamaru; E Kakishita
Journal:  Int J Hematol       Date:  1997-10       Impact factor: 2.490

5.  Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study.

Authors:  M A Hamidou; S Derenne; M A Audrain; J M Berthelot; A Boumalassa; J Y Grolleau
Journal:  Rheumatology (Oxford)       Date:  2000-04       Impact factor: 7.580

6.  Remitting seronegative symmetrical synovitis with pitting oedema in a patient with myelodysplastic syndrome and relapsing polychondritis.

Authors:  P Manganelli; G Delsante; G Bianchi; P Fietta; F Quaini
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

7.  Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis.

Authors:  Duojia Cao; Vivianne Malmström; Clare Baecher-Allan; David Hafler; Lars Klareskog; Christina Trollmo
Journal:  Eur J Immunol       Date:  2003-01       Impact factor: 5.532

8.  Myelodysplastic syndrome and pancytopenia responding to treatment of hyperthyroidism: peripheral blood and bone marrow analysis before and after antihormonal treatment.

Authors:  Riad Akoum; Saade Michel; Tabbara Wafic; Brihi Emile; Masri Marwan; Habib Khaled; Abadjian Gerard
Journal:  J Cancer Res Ther       Date:  2007 Jan-Mar       Impact factor: 1.805

9.  Cutaneous manifestations in relation to immunologic parameters in a cohort of primary myelodysplastic syndrome patients.

Authors:  M Dalamaga; K Karmaniolas; A Matekovits; I Migdalis; E Papadavid
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-12-07       Impact factor: 6.166

10.  Dermatomyositis and myelodysplastic syndrome with myelofibrosis responding to methotrexate therapy.

Authors:  Goh Tsuji; Soichiro Maekawa; Katsuyasu Saigo; Yumiko Nobuhara; Tomoko Nakamura; Seiji Kawano; Masahiro Koshiba; Shunichiro Asahara; Tadanobu Chinzei; Shunichi Kumagai
Journal:  Am J Hematol       Date:  2003-11       Impact factor: 10.047
View more
  22 in total

1.  Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts.

Authors:  Pragya Srivastava; Benjamin E Paluch; Junko Matsuzaki; Smitha R James; Golda Collamat-Lai; Julia Karbach; Michael J Nemeth; Pietro Taverna; Adam R Karpf; Elizabeth A Griffiths
Journal:  Leuk Res       Date:  2014-09-10       Impact factor: 3.156

2.  Impact of azacitidine on red blood cell alloimmunisation in myelodysplastic syndrome.

Authors:  Sebastián Ortiz; Maria T Orero; Karla Javier; Carolina Villegas; Irene Luna; Pedro Pérez; Mónica Roig; María López; Sofía Costa; Félix Carbonell; Rosa Collado; David Ivars; Mariano Linares
Journal:  Blood Transfus       Date:  2016-06-24       Impact factor: 3.443

3.  Remission of anti-TIF1γ dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome.

Authors:  Fatima Bawany; Bushra Tbakhi; Jason H Mendler; Christopher T Richardson; John M Bennett; Omar S Aljitawi
Journal:  Blood Adv       Date:  2020-11-24

4.  Dynamic alterations of bone marrow cytokine landscape of myelodysplastic syndromes patients treated with 5-azacytidine.

Authors:  Alena Moudra; Sona Hubackova; Veronika Machalova; Marketa Vancurova; Jiri Bartek; Milan Reinis; Zdenek Hodny; Anna Jonasova
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

Review 5.  Inflammation: a key regulator of hematopoietic stem cell fate in health and disease.

Authors:  Eric M Pietras
Journal:  Blood       Date:  2017-09-05       Impact factor: 22.113

6.  Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study.

Authors:  S Deshayes; E Liozon; N Chanson; K Sacré; T Moulinet; C Blanchard-Delaunay; O Espitia; M Groh; M Versini; T Le Gallou; J-E Kahn; V Grobost; S Humbert; M Samson; R Mourot Cottet; K Mazodier; A Dartevel; J Campagne; A Dumont; B Bienvenu; M Lambert; A Daumas; D Saadoun; A Aouba; H de Boysson
Journal:  Clin Rheumatol       Date:  2019-01-07       Impact factor: 2.980

7.  A medical mirroring: chronic myelomonocytic leukemia mimicking immunoglobulin G4-related disease.

Authors:  Zhiqian Bai; Yuxue Chen; Xiaoqi Chen; Lingli Dong
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 8.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

Review 9.  Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms.

Authors:  Daniel Arthur Corpuz Fisher; Jared Scott Fowles; Amy Zhou; Stephen Tracy Oh
Journal:  Front Immunol       Date:  2021-06-01       Impact factor: 8.786

10.  Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia.

Authors:  Manuel Molina; Sarvari Yellapragada; Martha Mims; Effie Rahman; Gustavo Rivero
Journal:  Case Rep Hematol       Date:  2015-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.